Research Program


NEW EXTENDED APPLICATION DEADLINE:  September 8, 2015 at midnight, CDT.

The Vasculitis Foundation would like to remind you of the availability of funding for vasculitis research for the 2016 funding cycle through our research program which funds research worldwide.

  We are pleased to introduce our new online application process.  The online application will allow you to review the program’s guidelines, copy/paste information into the text boxes and upload files, appendices and supporting documents as needed.  You can also save the application and come back to it as many times as you want before submitting.   Click here to access the online portal

IF you have any questions or problems with the application process, please contact Joyce A. Kullman, VF Executive Director:  

NEW DEADLINE:  Due to the delay in launching the new online application process, we are extending the application deadline to Tuesday, September 8, 2015 at midnight CDT.

The purpose of the Vasculitis Foundation Research Program is to provide one- or two-year seed grants to support pilot studies in researching:

  • Etiology/Pathogenesis (could include a broad range of studies of immunity, inflammation, or vascular biology. Relevance to human vasculitis will be taken into account by the reviewers.)
  • Epidemiology, including genetics
  • Diagnosis, including identification of disease subtypes
  • Treatment/Management, including therapeutics to treat vasculitis or prevent complications, biomarkers, and psychosocial outcomes

The goals of the Research Program are to improve the quality of life for patients with vasculitis and ultimately find the cause/s and cure for vasculitis.

The Research Program is funded by donations and special fundraising events.

Maximum awards will be $50,000 for 12 months. Some awards will be available for two years at a maximum of $50,000 per year.  Among applications with similar scores, preference will be given to applications with total budgets of $50,000 or less, to ensure that the Foundation can support as many investigators, and as many approaches to research in vasculitis as possible. . The Foundation’s hope is that the results of the research supported by the Research Program will lead to, and provide the basis for, much larger multi-year studies that would be funded by larger agencies such as The US National Institutes of Health (NIH).

International Funding Available:  The Vasculitis Foundation VF Research Program funds research worldwide.

Applications are reviewed annually. The deadline for submitting applications for the 2016 funding cycle is Tuesday, September 8, 2015.  Awards will be announced in December with funding available early in 2016.

To review the grants awarded from 2011-2015, please  click here.

2012 Consensus Conference

The VF hosted the 2nd International Vasculitis Research Consensus Conference on Friday, April 20, 2012, at the Hilton Chicago, Illinois. Dr. Gary S. Hoffman, Cleveland Clinic Center for Vasculitis Care and Research, functioned as the program moderator and facilitator.

The purpose of the conference was to utilize the combined skills and experience of leading experts in vasculitis from different subspecialties and other scientific fields to evaluate the VF Research Program and explore new areas of inquiry that the Foundation should support over the next five years.

Click here to download the VF Research Consensus Conference Report 2012.

Grants awarded by the Vasculitis Foundation


Immune regulation by IL-6 in giant cell arteritis, $50,000.00
Jonathan Choy, PhD
Simon Fraser University, Burnaby, British Columbia

Longitudinal study of morbidity and mortality in vasculitis patients, $98,641.00 (2-year study)
Susan S. Hick, DSc
School of Medicine, Boston University

Role of LAMP-2 in tolerance to ANCA antigens, $50,000
Renate Kain, MD, PhD
Clinical Institute of Pathology, Medical University of Vienna


Rho-kinase Activity in Large Vessel Vasculitis, $50,000.00
Lindsay S. Lally, MD, Robert F. Spiera, MD
Department of Medicine, Hospital for Special Surgery, New York City

Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis, $50,000.00
Kimberly P. Liang, MD
Division of Rheumatology and Clinical Immunology, University of Pittsburgh

The Role of microRNA in a Novel Mouse Model of Vasculitis, $50,000.00
Carola Vinuesa, MD, MSc, PhD
Department of Pathogens and Immunity, Australian National University, Acton, Australia

Impact of Healthcare Utilization & Informal Caregiving for Primary Systemic Vasculitis: A National Perspective, $99,920.00
Carolyn T. Thorpe, PhD, MPH
Pharmacy and Therapeutics, University of Pittsburgh

Disease-specific dysregulation of miRNA in Granulomatosis with Polyangiitis (GPA/Wegener’s), $50,000.00
Susanne Schinke, MD
Department of Rheumatology and Clinical Immunology, University of Lubeck and Klinikum, University Hospital Schleswig-Holstein Campus Lubeck, Germany


Development of a uniform histology scoring system for Small Vessel CNS vasculitis in Childhood and Adulthood, $40,128.10
Susanne M. Benseler, MD, MSCE, PhD, Department of Pediatrics, Division of Rheumatology, The Hospital for Sick Children

Circulating microparticles as therapeutic targets of plasma exchange in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis, $99,206.00
Paul Brogan, BSc, MBCHB, MRCPCH, MSc, PhD, FRCPCH, Paediatric Rheumatology/Infectious Disease and Microbiology Unit, Institute of Child Health

To Understand Role of 14-3-3- in Giant Cell Arteritis, $49,000.00
Ritu Chakravarti, PhD, Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation


Exome sequencing in granulomatosis with polyangiitis (GPA, Wegener’s), $50,000.00
Sharon Chung, MD, MAS, Division of Rheumatology, University of California, San Francisco

Investigating the molecular mechanism for IL-25-driven Act1-dependent eosinophilic vasculitis, $50,000.00
Shadi Swaidani, PhD, Cleveland Clinic Lerner Research Institute

Small molecule therapeutics in Giant Cell Arteritis, $50,000.00
Cornelia Weyand, MD, PhD, Stanford University School of Medicine


Defining an animal model for the study of Wegener’s Granulomatosis, $75,000.00
Felipe Andrade, MD, PhD, The Johns Hopkins University, Baltimore, MD


Reproductive Health in Young Men and Women with Vasculitis, $49,978.00
Megan E. B. Clowse, MD, Rheumatology and Immunology, Duke University, Raleigh, NC

Classification and Diagnostic Criteria in Primary Systemic Vasculitis, $99,738.00
Raashid Ahmed Luqmani, MD, Nuffield Department of Orthopaedics Rheumatology & Musculoskeletal Science Oxford, United Kingdom

Identification of susceptibility genes in Takayasu’s arteritis, $50,000.00
Amr H. Sawalha, MD, Oklahoma City, OK


PARP-1 in CSS-associated IL-10 Promoter Polymorphisms, $50,000.00
Jianguo Liu, MD, PhD, Division of Immunobiology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO


Vasculitic T Cells in Giant Cell Arteritis, $99,583.00 
C.M. Weyand, MD, Emory University, Atlanta, Georgia

An Investigation of the Role of the Innate Immune Response in Kawasaki Disease, $49,980.00
Neil Bowles, PhD, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, UT

Investigating the role of the novel Th 17 cells in the pathogenesis of ANCA associated vasculitis and their potential for immunomodulation, $48,000.00
Alan Salama, MBBS, PhD, FRCP, Renal Section, Division of Medicine Imperial College London, England

ANCA Vasculitis:  Autoimmune B Cell dysregulation and its Clinical Impact, $50,000.00
Patrick Nachman, MD, University of North Carolina Kidney Center, Chapel Hill, NC
Expression and activation of p38MAPK isoforms in ANCA-associated renal vasculitis, $50,000.00
Jochen Zwerina, MD, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen, Germany


Identification and characterization of immunodominant, conformational epitopes of antineutrophil cytoplasmic antibodies, $35,000.00
Antje Mueller, MD, Csernok, MD, Peter Lamphrect, MD
University of Rheumatology, University Hospital Schleswig-Holstein, Campus Luebeck, Germany

Gene Expression Profile of Temporal Arteries of Giant Cell Arteritis, $35,000.00
Rula Hajj-Ali, MD, Cleveland Clinic, Cleveland, OH

Environmental Factors in the Pathogenesis of Wegener’s Granulomatosis, $35,000.00

Daniel Albert, MD, University of Pennsylvania School of Medicine, Philadelphia, PA

Localized Wegener’s Granulomatosis: Epidemiological, clinical and histopathological characteristics, $30,000.00
Peer Malte Aries, MD, and Prof. Wolfgang L. Gross, MD
Department of Rheumatology, University Hospital of Schleswig-Holstein

A Pilot Project Towards Establishment of a US/Canadian Diagnostic Registry of  Children with Wegener’s Granulomatosis and Related Vasculitides, $34,900.00
David A. Cabral, MBBS, BC Children’s Hospital, Vancouver, BC, Canada

Renal transplantation in Wegener’s granulomatosis: mortality, allograft outcomes  and incidence of malignancies from the United Network for Organ Sharing database 1988-2005, $16,000.00
Nadine Tanenbaum, MD, Duke University, Raleigh, NC


Identification of novel Wegener’s Granulomatosis Susceptibility Genes, $35,000.00

Katherine Siminovitch, PhD,  Mount Sinai Hospital, Toronto, ON, Canada

Wegener’s Granulomatosis and Microscopic Polyarteritis Case Control Study in Western Montana, $7,500.00
Andrew Zeft, MD, Division of Immunology and Rheumatology, Department of Pediatrics, University of Utah, Salt Lake City, UT

Development of a Measure to Assess Patients’ Adherence to Vasculitis Treatment Regimens, $35,000.00
Robert DeVellis, PhD, Associate Director, Arthritis Multidisciplinary Clinical Research Center, University of North Carolina, Chapel Hill, NC

Analysis of NKG2D expression on CD28- T-cells and non-classical MHC-class I antigen expression on antigen-presenting cells as clues to an antigen-driven process and new targets of treatment in Wegener’s granulomatosis, $35,000.00
Prof. Wolfgang L. Gross, MD, and Peter Lamprecht, MD
Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, and Rheumaklinik Bad Bramstedt


The role of shear stress in neutrophil proteinase-3 expressionand its importance in vascular injury sites in Wegener’s granulomatosis, $35,000.00
Deborah Stearns-Kurosawa, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK


Host-microbial interactions in Wegener’s Granulomatosis: the role of ANCA and S. aureus persistence, $35,000.00
Robert Inman, MD, University of Toronto, Canada

Short-Term Cyclophosphamide Therapy in a Cohort of Over 200 Patients, $35,000.00
Gary Hoffman, MD, MS and Alexandra Villa-Forte, MD, MPH, The Cleveland Clinic, Cleveland, OH

Grants Management System provided by WizeHive

About Author: admin

Medical Search Tools

Enter your search terms in this tool and the results will open in a new tab or window.

Participation in Clinical Trials is one way you can help advance research into finding better treatments and perhaps even a cure for vasculitis!
Learn how you can participate in clinical trials - National Institutes of Health

VCRC-VF Fellowship Program

The Vasculitis Clinical Research Consortium-Vasculitis Foundation Fellowship is a mentored training program of up to two years for physician-investigators who have a strong interest in vasculitis and wish to pursue a period of specialized training with an emphasis on clinical and/or translational patient-oriented clinical investigation.

The trainee will undertake the Fellowship between 2014-2019 at a VCRC-affiliated site in North America that has an established distinct clinical and research program in vasculitis and availability of senior faculty mentors.

"The Vasculitis Foundation is committed to creating greater awareness and interest in vasculitis," said Joyce Kullman, executive director of the VF. "We hope that the VCRC-VF Fellowship will encourage medical professionals to pursue careers in patient care and research linked to vasculitis."

To support the VCRC-VF Fellowship, please visit the donate page.

Medical Institutions

The Vasculitis Foundation encourages vasculitis patients to seek expert medical care for diagnosis and treatment of the disease. The VF works closely with vasculitis experts and centers around the world to ensure patients have access to the most up-to-date medical care.

The Vasculitis Clinical Research Consortium (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis and improving the care of patients with vasculitis.